知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

9 records (took 0.024 seconds)

    Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
    2.
    发明授权
    Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease 有权
    使用抗EGFR抗体治疗EGFR突变介导的疾病

    公开(公告)号：US09090693B2

    公开(公告)日：2015-07-28

    申请号：US12449129

    申请日：2008-01-24

    Applicant: Kwok-Kin Wong

    Inventor： Kwok-Kin Wong

    IPC: C07K16/28 ,  A61K39/00

    CPC classification number: C07K16/2863 ,  A61K2039/505

    Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies. Methods for treatment of cancer and reduction of tumor growth in individuals with secondary EGFR mutations, particularly tyrosine kinase domain mutations, resistant to standard therapy are provided. The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies. Methods for treatment of recurrent lung cancer, including non-small cell lung carcinoma which is resistant to tyrosine kinase inhibitors, with the antibody anti-EGFR mAb806 are described.

    Abstract translation: 本发明涉及对酪氨酸激酶抑制剂治疗具有抗性的EGFR介导的疾病，特别是癌症的治疗。 提供了治疗癌症的方法和减少具有继发性EGFR突变，特别是酪氨酸激酶结构域突变的个体的肿瘤生长，其对标准治疗具有抗性。 本发明提供了用抗EGFR抗体治疗酪氨酸激酶抑制剂抗性癌症的方法。 描述了用抗体抗EGFR mAb806治疗复发性肺癌，包括对酪氨酸激酶抑制剂具有抗性的非小细胞肺癌的方法。

    Susceptibility to HSP90-Inhibitors
    8.
    发明申请
    Susceptibility to HSP90-Inhibitors 审中-公开
    对HSP90抑制剂的敏感性

    公开(公告)号：US20110319415A1

    公开(公告)日：2011-12-29

    申请号：US13059557

    申请日：2009-08-17

    Applicant: Roman Thomas ,  Kathrin Maring ,  Thomas Zander ,  Peter Frommolt ,  Kwok-kin Wong

    Inventor： Roman Thomas ,  Kathrin Maring ,  Thomas Zander ,  Peter Frommolt ,  Kwok-kin Wong

    IPC: A61K31/395 ,  C12Q1/68 ,  G01N33/567 ,  A61K31/5377 ,  A61P35/00 ,  A61P35/02 ,  C40B30/04 ,  C12Q1/02

    CPC classification number: G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N2800/52

    Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and. optionally, in the EGFR gene and/or the BRAF gene. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one activating mutation in the KRAS gene, and, optionally, in the EGFR gene and/or the BRAF gene for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.

    Abstract translation: 本发明涉及一种选择（a）对HSP90抑制剂具有敏感性的细胞，（a）组织或（a）细胞培养物的方法。 本文还描述了确定哺乳动物肿瘤细胞或癌细胞对用HSP90抑制剂进行治疗的反应性的方法。 特别地，本发明提供了用于鉴定对HSP90抑制剂敏感的或对其敏感的患者的体外方法，以及能够检测（或）激活KRAS基因突变的寡核苷酸或多核苷酸的用途 被提供。 本发明还涉及一种监测癌症治疗功效的方法，其特征在于在KRAS基因中存在至少一种激活突变。 任选地，在EGFR基因和/或BRAF基因中。 此外，描述了预测癌症治疗功效的方法，特别是在KRAS基因中存在至少一种激活突变的癌症中。 和。 任选地，在EGFR基因和/或BRAF基因中。 另外，在KRAS基因和/或任选地在EGFR基因和/或BRAF基因中具有至少一个激活突变的（转基因）非人动物或（转基因）细胞也用于筛选和/或验证 描述了用于治疗所述癌症的药物，并提供了可用于实施本文所述方法的试剂盒。

    USE OF ANTI-EGFR ANTIBODIES IN TREATMENT OF EGFR MUTANT MEDIATED DISEASE
    9.
    发明申请
    USE OF ANTI-EGFR ANTIBODIES IN TREATMENT OF EGFR MUTANT MEDIATED DISEASE 有权
    使用抗EGFR抗体治疗EGFR突变介导的疾病

    公开(公告)号：US20100166744A1

    公开(公告)日：2010-07-01

    申请号：US12449129

    申请日：2008-01-24

    Applicant: Kwok-Kin Wong

    Inventor： Kwok-Kin Wong

    IPC: A61K39/395 ,  A61P35/00

    CPC classification number: C07K16/2863 ,  A61K2039/505

    Abstract: The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies. Methods for treatment of cancer and reduction of tumor growth in individuals with secondary EGFR mutations, particularly tyrosine kinase domain mutations, resistant to standard therapy are provided. The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies. Methods for treatment of recurrent lung cancer, including non-small cell lung carcinoma which is resistant to tyrosine kinase inhibitors, with the antibody anti-EGFR mAb806 are described.

    Abstract translation: 本发明涉及对酪氨酸激酶抑制剂治疗具有抗性的EGFR介导的疾病，特别是癌症的治疗。 提供了治疗癌症的方法和减少具有继发性EGFR突变，特别是酪氨酸激酶结构域突变的个体的肿瘤生长，其对标准治疗具有抗性。 本发明提供了用抗EGFR抗体治疗酪氨酸激酶抑制剂抗性癌症的方法。 描述了用抗体抗EGFR mAb806治疗复发性肺癌，包括对酪氨酸激酶抑制剂具有抗性的非小细胞肺癌的方法。

Patent Agency Ranking